Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 3(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06529718Phase 2Recruiting

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Role: collaborator

NCT05615818Phase 3Recruiting

Personalized Medicine for Advanced Biliary Cancer Patients

Role: collaborator

NCT05255653Phase 2Recruiting

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

Role: collaborator

NCT00678327Phase 3Completed

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Role: collaborator

All 4 trials loaded